Current and historical daily PE Ratio for Sunshine Biopharma Inc (
) from 2022 to Jun 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Sunshine Biopharma stock (SBFMW) PE ratio as of Jun 24 2024 is 0.
More Details
Sunshine Biopharma Inc (SBFMW) PE Ratio (TTM) Chart
Sunshine Biopharma Inc (SBFMW) PE Ratio (TTM) Historical Data
View and export this data going back to 2022. Start your Free Trial
Total 0
- 1
Sunshine Biopharma PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
Sunshine Biopharma Inc (SBFMW) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
![Sunshine Biopharma Inc Sunshine Biopharma Inc logo](https://static.gurufocus.com/logos/0C00002AJZ.png?14)
Sunshine Biopharma Inc
NAICS : 325412
SIC : 2834
Share Class Description:
SBFMW: Warrants (15/02/2027)Description
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.